Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma | 2 Minute Medicine
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Overall survival in patients receiving bortezomib or dexamethasone with... | Download Scientific Diagram
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD - CDCN
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Relapsed: D + VD Treatment | DARZALEX® IV (daratumumab)
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma | Published in Journal of Health Economics and Outcomes Research
Cancers | Free Full-Text | Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
BOSTON trial (SVd) Update at ASCO 2020 | Int Myeloma Fn
Treatment of Relapsed/Refractory Multiple Myeloma with Bendamustine, Bortezomib and Dexamethasone | Research To Practice
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis - Biology of Blood and Marrow Transplantation
British Journal of Haematology | Wiley Online Library
